Details

Autor(en) / Beteiligte

• Spizzo, Gilbert
• Seeber, Andreas
• Mitterer, Manfred

Titel

Routine Use of Pamidronate in NSCLC Patients with Bone Metastasis: Results from a Retrospective Analysis

Ist Teil von

• Anticancer research, 2009-12, Vol.29 (12), p.5245-5250

Ort / Verlag

Greece: International Institute of Anticancer Research

Erscheinungsjahr

2009

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Background: No data on the tolerability and effects of pamidronate in non-small cell lung cancer patients with bone metastasis are available. We performed a retrospective analysis to evaluate the routine use of pamidronate in these patients. Patients and Methods: One hundred and four patients with NSCLC were treated at our Day Hospital between May 2003 and February 2009. Forty-one (39.5%) presented with bone metastasis during the course of the disease. Thirty (73.2%) of these patients received pamidronate at a dose of 90 mg every four weeks. Results: The occurrence of bone metastasis was associated with a poor overall survival, but patients treated with pamidronate had a significantly better median overall survival than untreated patients (15.4 months vs. 2.1 months; p<0.001). Pamidronate was well tolerated and only grade 1 or 2 toxicities were registered. Conclusion: The diagnosis of bone metastasis and the consequent routine administration of pamidronate have an impact on survival of NSCLC patients; this drug is a good candidate for routine use in haemato-oncological centres.